Company intelligence / Profile preview

CryoCord

Cyberjaya, Selangor, Malaysiacryocord.com.my ↗

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

CryoCord operates one of Southeast Asia’s largest private stem cell banks, with over two decades of experience. It has performed Malaysia’s first successful sibling cord blood transplant for leukemia, launched the region’s first range of MSC products from various tissues, expanded into immune cell banking, and received regulatory approval for clinical trials in advanced cellular therapies such as CAR T-cells. The company holds multiple patents in the field.[1]

Therapeutic areas: OtherHematology
Modalities: Stem cells (umbilical cord blood, mesenchymal stem cells)Immune cells (natural killer cells, CAR T-cells)[1]
Industry: Biotech

Drug pipeline

1 asset

PF2020-CELL

Partnerships

Collaborations with Intan Medical Centre, Pantai Group of Hospitals, Universiti Sains Malaysia; MoUs signed for cryopreservation/research partnerships.[5]

Beyond the preview

Go deeper on CryoCord.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CryoCord.